CytoSorbents Clinches $2 Million Series A Funding to Power Breakthroughs in Critical Care Solutions

CytoSorbents Corporation, a pioneering New Jersey-based company renowned for its proprietary polymer adsorption technology, is thrilled to announce a successful funding round that has raised $2,000,000. This substantial investment represents not only a vote of confidence in CytoSorbents’ innovative approach to medical device research and commercialization but also a milestone that will accelerate the advancement of life-saving therapies. For years, the company has been at the forefront of improving patient outcomes in intensive care units and during cardiothoracic surgeries through its flagship product, CytoSorb®. This breakthrough device, now distributed in over 70 countries and approved with a CE Mark in the EU, effectively removes cytokines, bilirubin, and myoglobin in various critical care applications, as well as antithrombotic agents such as ticagrelor and rivaroxaban during surgical procedures. With multiple clinical trials well underway—including two pivotal randomized controlled trials in the United States aimed at FDA approval for its DrugSorb™-ATR Antithrombotic Removal System—CytoSorbents is strategically positioned to expand its therapeutic offerings. The new funds will primarily support the enhancement of these clinical trials, thereby bolstering the development pipeline and streamlining regulatory pathways. By reinforcing its research infrastructure and propelling forward its commercialization efforts, CytoSorbents aspires to bring transformative solutions to the management of life-threatening conditions, ultimately saving more lives and reinforcing its global leadership in blood purification technologies. This financial boost underscores the company’s unwavering commitment to innovation and patient care, driving forward a future where advanced medical treatments become a standard of excellence in critical care worldwide.